ArriVent BioPharma, Inc. (AVBP) vs SOPHiA GENETICS S.A. (SOPH)
A side-by-side comparison of ArriVent BioPharma, Inc. and SOPHiA GENETICS S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SOPH
SOPHiA GENETICS S.A.
$7.38HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AVBP vs SOPH
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)SOPH +69.1% (+19.1%/yr)SOPH compounded faster over this window
AVBP SOPH
AVBP vs SOPH: by the numbers
- •AVBP is the larger company ($703M vs $619M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -93.86% net margin).
Metrics side by side
Valuation
| Metric | AVBP | SOPH |
|---|---|---|
| P/S ratio | N/A | 7.19 |
| P/B ratio | 1.92 | 7.45 |
Profitability
| Metric | AVBP | SOPH |
|---|---|---|
| Gross margin | 0.00% | 66.63% |
| Operating margin | 0.00% | -85.01% |
| Net margin | 0.00% | -93.86% |
| ROE | -44.63% | -97.31% |
| ROIC | -47.96% | -49.73% |
Growth (annualized)
| Metric | AVBP | SOPH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.33% |
| Total return CAGR (5Y) | N/A | -13.62% |
Go deeper
Dig into the metrics
ArriVent BioPharma ROESOPHiA GENETICS ROEArriVent BioPharma operating marginSOPHiA GENETICS operating marginArriVent BioPharma revenue growthSOPHiA GENETICS revenue growthArriVent BioPharma free cash flowSOPHiA GENETICS free cash flow
ArriVent BioPharma & SOPHiA GENETICS appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.